If you've used a compounded GLP-1, you've injected a medication that was mixed from raw ingredients at a pharmacy — not stamped out on the same production line as a branded pen. That distinction shapes everything about how the two are made, tested, and regulated. Here's what actually happens between a barrel of drug powder and the vial in your hand, and how the compounded route compares with the branded one at each step.
What "compounding" actually means
Compounding is the practice of a licensed pharmacy combining or altering ingredients to make a medication for a patient. For GLP-1s, that means starting with the active pharmaceutical ingredient (API) — the drug substance itself, as a powder — and turning it into an injectable solution. This is a fundamentally different activity from manufacturing an FDA-approved drug: a manufacturer makes millions of identical, pre-tested units under federal approval, while a compounder prepares a product that has never been reviewed by the FDA for safety, effectiveness, or quality before it reaches you.
There are two kinds of facility allowed to do this, and the difference matters:
- 503A pharmacies are state-licensed, compound against an individual prescription for a named patient, are inspected mainly by the state board of pharmacy, and follow the U.S. Pharmacopeia (USP) standards for compounding — including USP <797> for sterile products. They are not required to follow the federal "current good manufacturing practice" (CGMP) rules that manufacturers must.
- 503B outsourcing facilities register directly with the FDA, can compound larger batches without a patient-specific prescription, and must meet full CGMP and risk-based FDA inspection — a step closer to a manufacturer, but still not making an FDA-approved drug.
Step 1: Sourcing the active ingredient
A legitimate compounder can't just buy GLP-1 powder from anywhere. The API is supposed to be pharmaceutical-grade, come with a valid certificate of analysis documenting its identity and purity, and be made by an establishment registered with the FDA (under section 510 of the federal drug law). Reputable pharmacies send finished product to third-party labs and source raw material from FDA-registered suppliers to try to hold that line.
This is also where one of the biggest safety problems lives — the salt-form issue. The FDA has warned that "salt" versions of the drug substance, such as semaglutide sodium and semaglutide acetate, are different active ingredients than what's in the approved medications. The agency says it has no information showing these salts behave the same way in the body, and is not aware of a lawful basis for using them in compounding. Several state pharmacy boards have gone further and prohibited compounding with semaglutide salts or with any API that isn't pharmaceutical-grade and FDA-registered. When you hear cautions about "research peptides" and grey-market powder, this is the core of it: the label on the drum, and where it really came from, is the whole ballgame. (Our guide on research peptides and GLP-1 medications covers the grey-market end of this in detail.)
Step 2: Determining the formula and dose
In a 503A setting, the formula starts with a prescription for a specific patient. The prescriber sets the drug, the concentration, and the dose; the pharmacy works out how to dissolve the API to that concentration in a sterile carrier — typically sterile water or a buffered saline solution — sometimes with other excipients to keep the peptide stable. Some compounded products are formulated at concentrations or in drug combinations (for example, paired with vitamin B12) that don't exist in any branded pen.
That flexibility is exactly why compounding exists — and also where risk creeps in. Because a compounded vial isn't a fixed-dose pen, the patient often has to draw up a dose with a syringe, and the concentration may differ from what they're used to. The FDA has received reports of dosing errors — some serious enough to require hospitalization — tied to compounded injectable semaglutide, several traced to patients measuring the wrong amount. A branded pen removes that math; a compounded vial reintroduces it.
Step 3: How the pharmacy actually makes it
The physical process, in a sterile 503A or 503B cleanroom operating under USP <797>, looks roughly like this:
- Dissolve the API powder into the sterile carrier at the target concentration.
- Sterile-filter the solution, usually through a 0.22-micron filter that removes bacteria.
- Aseptically fill the solution into sterile vials in a controlled, clean environment.
- Test representative units — reputable operations send samples to third-party labs for potency (is the dose accurate?), sterility (is it free of microbes?), and endotoxin (is it free of the bacterial wall fragments that can cause fever and serious reactions?).
The gap between best practice and worst practice here is enormous, and it's invisible to the patient holding the vial. A careful 503B facility under CGMP tests every batch; a cut-corner operation may test little and document less. Nothing about the finished vial's appearance tells you which one you got — which is why the source matters more than the product looks like it should.
How the branded pens are made
The branded medications — Ozempic and Wegovy (semaglutide, Novo Nordisk), Zepbound and Mounjaro (tirzepatide, Eli Lilly) — are made on an entirely different scale and under an entirely different rulebook.
- The drug substance is produced under tight control. Semaglutide is a peptide assembled through large-scale, controlled processes — Novo Nordisk produces it using recombinant/biotechnology methods combined with chemical steps at its facilities in Denmark; tirzepatide is likewise made through controlled peptide synthesis. This isn't powder ordered from a supplier; it's produced in-house to a fixed specification.
- Every step meets CGMP and FDA approval. The formula and dose aren't set per patient — they're fixed, studied in clinical trials, and approved by the FDA before a single pen is sold. Every batch is made and tested under federal good-manufacturing rules.
- Fill-finish is industrial and standardized. The drug is filled into prefilled pens (or vials) at large plants — Novo fills and finishes at sites in Denmark, France, and North Carolina — and each unit delivers the same metered dose.
- It's slow by design. Novo has described the full process, from production to finished pen, as taking on the order of 250 to 280 days — one reason branded shortages take months, not days, to resolve.
The through-line: a branded pen is one of millions of identical units, each vetted before it ships. A compounded vial is a small batch prepared after the prescription is written, vetted (if at all) by the pharmacy and its labs rather than by the FDA.
Where compounded GLP-1s stand now
Compounding of these drugs surged because the branded products were in official shortage — a status that, under federal law, opens a window for compounders. As the shortages resolved in 2025, that window narrowed sharply. The FDA ended enforcement discretion for compounded tirzepatide in 2025, leaving patient-specific 503A compounding as the only remaining route for it, and the picture for semaglutide has tightened along similar lines. Because this legal status has already shifted more than once and continues to move, treat it as something to re-check against current, dated FDA guidance rather than a settled fact.
If you are using or considering a compounded GLP-1, the practical safeguard is to vet the pharmacy: confirm it's a licensed 503A pharmacy or FDA-registered 503B facility, ask what API it uses and whether it's the base drug (not a salt), and ask for third-party testing. Our guides on pharmacy sources for GLP-1 medications and how to verify a pharmacy is legitimate walk through exactly how.
The bottom line
The difference between a compounded GLP-1 and a branded pen isn't the molecule on the label — it's everything around it: who made the raw ingredient and whether it's the real active drug, whether the dose was set for you or fixed by a manufacturer, whether the sterile process was verified batch-by-batch, and whether any federal body reviewed the finished product before you injected it. Legitimate compounding is a real, regulated pharmacy activity with a genuine role. But the safeguards that come standard with a branded pen are, in the compounded world, only as good as the specific pharmacy behind the vial — which is why sourcing is the part worth your attention.
This article is general education, not medical advice. Regulations governing compounded GLP-1 medications are changing; confirm current status and any specific product with the FDA, your prescriber, or your pharmacist before acting.